Orthofix International Announces Limited Market Release of Trinity(R) Evolution(TM) and Completion of First Surgical Procedure Using New Stem Cell-Bas
BOSTON, May 05, 2009 (BUSINESS WIRE) — Orthofix International N.V. (NASDAQ: OFIX) (the Company) announced today that the Company has begun the limited market release of Trinity(R) Evolution(TM) in collaboration with the Musculoskeletal Transplant Foundation (MTF). Trinity Evolution is a stem cell-based bone growth matrix designed to advance the surgical use of allografts by providing characteristics similar to an autograft in spinal and orthopedic procedures.
“We are extremely pleased to announce that we have begun to make Trinity Evolution available to our surgeon customers. The initial feedback we have received on Trinity Evolution has been extraordinarily positive, and we look forward to our full market release by July 1, 2009,” said Alan Milinazzo, President and CEO of Orthofix International.
Dr. Steve Yocom completed the first procedure using Trinity Evolution on April 28th. The 46-year-old patient underwent a lumbar spine fusion procedure at Cooper University Hospital in Camden, NJ. Since commencing our limited release, Trinity Evolution has been implanted in a variety of spinal and orthopedic procedures by several leading surgeons around the country, including Dr. Michael Zindrick, Dr. Mark Lorenz, Dr. Christopher Bibbo, Dr. Daniel Lee and Dr. Jamie Gottlieb.
“Trinity Evolution is an excellent new tissue form that should be of great benefit to patients and the doctors who serve them,” said Bruce Stroever, President and CEO of MTF.
Trinity Evolution is used by surgeons to facilitate bone fusion, and will be marketed exclusively by Orthofix Spinal Implants and Orthofix Orthopedics. MTF is responsible for the recovery of donor tissue, the processing of the bone growth matrix, and for the fulfilment of orders received.
Orthofix anticipates completing the full market release of Trinity Evolution by July 1st of this year.
